OmniSeq Comprehensive® Assay
A next generation sequencing (NGS) assay that tests tumor DNA and RNA to identify somatic mutations in 144 genes for solid tumors to help guide targeted therapeutic management for patients with cancer.1
The assay measures all types of relevant variants (SNVs, CNV, fusions) for a comprehensive assessment of the tumor1
|OmniSeq Comprehensive Assay - Genes and NGS Technologies|
|DNA-Sequencing (DNA-Seq)||RNA-Sequencing (RNA-Seq)|
(SNVs, insertions and deletions)
|Copy Number Variants
(gains and losses)
A proprietary pre-analytical process enables a very low sample input requirement (1 ng–30 ng), thus obtaining a very low quantity not sufficient (QNS) result rate compared to other comprehensive genomic profiling assays2,3,4
Please see the test menu for additional specimen and test information.
The OmniSeq Comprehensive® assay was developed by OmniSeq® and is performed by OmniSeq as a send-out from Integrated Oncology, part of LabCorp Specialty Testing Group, its US distributor.
1. OmniSeq website. https://www.omniseq.com/comprehensive/. Accessed 5/21/18.
2. OmniSeq website, Case Study. https://www.omniseq.com/wp-content/uploads/2016/09/OmniSeq-QNS-Case-Study_t.pdf. Accessed 11/2/17.
3. Zehir, A et al., Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017. 23:703–713.
4. Frampton, GM, et al., Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013, 31:1023-31.